MARKET

IDYA

IDYA

Ideaya Bioscienc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.49
-0.44
-1.84%
Closed 16:00 07/29 EDT
OPEN
24.21
PREV CLOSE
23.93
HIGH
24.55
LOW
23.24
VOLUME
140.28K
TURNOVER
--
52 WEEK HIGH
26.00
52 WEEK LOW
10.90
MARKET CAP
883.31M
P/E (TTM)
-19.1990
1D
5D
1M
3M
1Y
5Y
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commissions, including the exer...
PR Newswire · 07/12 20:11
IDEAYA Prices 4.6M Common Stock Offering; Street Says Buy
IDEAYA Biosciences, Inc. (IDYA) announced the pricing of an underwritten public offering of its approximately 4.6 million shares of common stock at $17.25 per share. The stated price excludes underwriting discounts and commissions. The company has given un...
SmarterAnalyst · 07/08 10:39
Ideaya secures $80M capital via equity raise
IDEAYA Biosciences (IDYA) has priced its public offering of 4,637,681 common shares at $17.25/share, for expected gross proceeds of ~$80M.Underwriters' over-allotment is an additional 695,652 shares. Net proceeds will be
Seekingalpha · 07/08 06:08
IDEAYA Biosciences Prices Offering at $17.25/Share, Expects $80 Million Gross Proceeds
MT Newswires · 07/08 03:50
BRIEF-Ideaya Announces Pricing Of Public Offering Of Common Stock
reuters.com · 07/08 01:31
IDEAYA Announces Pricing of Public Offering of Common Stock
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at a public offering price of $17.25 per share, before underwriting discounts and commissions. In addition, IDEAYA...
PR Newswire · 07/08 01:29
Mid-Afternoon Market Update: Dow Rises 70 Points; IDEAYA Biosciences Shares Slide
Toward the end of trading Wednesday, the Dow traded up 0.20% to 34,647.52 while the NASDAQ rose 0.01% to 14,664.04. The S&P also rose, gaining 0.33% to 4,358.01.
Benzinga · 07/07 18:52
BTU, ONCS, DARE among mid-day movers
Newegg Commerce (NEGG) +115%.Dare Bioscience DARE +35%.Opiant Pharmaceuticals OPNT +32%.Data Storage (DTST) +32%.OncoSec Medical ONCS +30%.Peabody Energy (BTU) +27%.iPower (IPW) +21%.SMART Global Holdings SGH +20%.Virpax Pharmaceuticals VRPX +18%.X Financi...
Seekingalpha · 07/07 17:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IDYA. Analyze the recent business situations of Ideaya Bioscienc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IDYA stock price target is 31.56 with a high estimate of 38.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 23.01M
% Owned: 61.18%
Shares Outstanding: 37.60M
TypeInstitutionsShares
Increased
31
2.14M
New
19
2.78M
Decreased
22
1.20M
Sold Out
12
267.96K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Timothy Shannon
President/Chief Executive Officer/Director
Yujiro Hata
Chief Financial Officer/Senior Vice President/IR Contact Officer
Paul Stone
Senior Vice President/Chief Scientific Officer
Michael Dillon
Senior Vice President/General Counsel/Secretary
Jason Throne
Vice President/Director of Human Resources
Julie Patel
Vice President
Paul Barsanti
Vice President
Matthew Maurer
Independent Director
M. Garret Hampton
Independent Director
Susan Kelley
Independent Director
Scott Morrison
Independent Director
Terry Rosen
Independent Director
Jeffrey Stein
Independent Director
Wendy Yarno
No Data
  • All
  • Financials
  • Insiders
More
About IDYA
IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company. The Company focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company’s product candidate is IDE196, a protein kinase C (PKC), inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes multiple synthetic lethality programs, including against methionine adenosyltransferase 2a (MAT2A) in tumor cells having methylthioadenosine phosphorylase (MTAP) gene deletion; Pol-theta, in tumors with genetic mutations in homologous recombination deficiency (HRD), including breast carcinoma (BRCA ) mutations; poly adenosine diphosphate-ribose glycohydrolase (PARG), in tumors with genetic mutations in BRCA or base excision repair, and WRN, in high microsatellite instability tumors (MSI) tumors.

Webull offers kinds of Ideaya Biosciences Inc stock information, including NASDAQ:IDYA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDYA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDYA stock methods without spending real money on the virtual paper trading platform.